CN104395322B - 含有利福昔明和氨基酸的药用组合物、其制备方法和用途 - Google Patents

含有利福昔明和氨基酸的药用组合物、其制备方法和用途 Download PDF

Info

Publication number
CN104395322B
CN104395322B CN201380033964.XA CN201380033964A CN104395322B CN 104395322 B CN104395322 B CN 104395322B CN 201380033964 A CN201380033964 A CN 201380033964A CN 104395322 B CN104395322 B CN 104395322B
Authority
CN
China
Prior art keywords
rifaximin
crystals
amino acid
amino acids
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380033964.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104395322A (zh
Inventor
G·C·维斯科米
L·彻拉茨
F·格雷皮奥尼
D·布拉加
M·金特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha Sigma Co ltd
Original Assignee
Alfa Wasserman SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46939741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104395322(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wasserman SpA filed Critical Alfa Wasserman SpA
Publication of CN104395322A publication Critical patent/CN104395322A/zh
Application granted granted Critical
Publication of CN104395322B publication Critical patent/CN104395322B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
CN201380033964.XA 2012-07-06 2013-07-03 含有利福昔明和氨基酸的药用组合物、其制备方法和用途 Expired - Fee Related CN104395322B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITBO2012A000368 2012-07-06
IT000368A ITBO20120368A1 (it) 2012-07-06 2012-07-06 Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
PCT/IB2013/055448 WO2014006576A1 (en) 2012-07-06 2013-07-03 Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof

Publications (2)

Publication Number Publication Date
CN104395322A CN104395322A (zh) 2015-03-04
CN104395322B true CN104395322B (zh) 2017-05-10

Family

ID=46939741

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380033964.XA Expired - Fee Related CN104395322B (zh) 2012-07-06 2013-07-03 含有利福昔明和氨基酸的药用组合物、其制备方法和用途

Country Status (24)

Country Link
US (2) US9452157B2 (enExample)
EP (2) EP2870163B1 (enExample)
JP (1) JP6150888B2 (enExample)
KR (1) KR101880255B1 (enExample)
CN (1) CN104395322B (enExample)
AU (1) AU2013285085B2 (enExample)
BR (1) BR112015000088B1 (enExample)
CA (1) CA2874815C (enExample)
CL (1) CL2015000019A1 (enExample)
DK (1) DK2870163T3 (enExample)
EA (1) EA028769B1 (enExample)
ES (1) ES2691971T3 (enExample)
IL (1) IL235992B (enExample)
IN (1) IN2014DN11207A (enExample)
IT (1) ITBO20120368A1 (enExample)
MX (1) MX366193B (enExample)
NZ (1) NZ703120A (enExample)
PL (1) PL2870163T3 (enExample)
PT (1) PT2870163T (enExample)
SG (1) SG11201408277UA (enExample)
TN (1) TN2014000530A1 (enExample)
UA (1) UA114512C2 (enExample)
WO (1) WO2014006576A1 (enExample)
ZA (1) ZA201408990B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ES2742106T3 (es) 2014-05-12 2020-02-13 Alfasigma Spa Nueva forma de cristal solvatado de rifaximina, producción, composiciones y usos de la misma
WO2016204474A2 (ko) * 2015-06-18 2016-12-22 주식회사대성미생물연구소 리팍시민 결정체를 포함하는 동물 장염 치료용 수의학적 조성물
WO2017134072A1 (en) * 2016-02-03 2017-08-10 Firmenich Sa Solutions and dispersions of amide compounds
HUE046449T2 (hu) 2016-09-13 2020-03-30 Allergan Inc Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények
MX387893B (es) * 2018-04-18 2025-03-19 Alparis Sa De Cv Nuevas fases solidas de rifaximina.
WO2020208140A1 (en) * 2019-04-12 2020-10-15 Sandoz Ag Rifaximin-containing granules
KR102154309B1 (ko) 2019-07-05 2020-09-09 주식회사 비오엑스 테이프 없이 포장가능한 포장상자
KR102312848B1 (ko) 2019-12-11 2021-10-15 주식회사 비오엑스 테이프 없이 포장가능한 포장상자
KR102252978B1 (ko) 2019-12-11 2021-05-18 주식회사 비오엑스 테이프 없이 포장가능한 포장상자
KR102182587B1 (ko) 2020-01-22 2020-11-24 주식회사 비오엑스 밀폐구조를 갖는 포장상자
EP4171520A1 (en) * 2020-06-26 2023-05-03 Bausch Health Ireland Limited Targeted release rifaximin compositions
KR20220151991A (ko) 2021-05-07 2022-11-15 주식회사 비오엑스 테이프 없이 포장 가능한 포장상자
KR102674188B1 (ko) 2022-01-13 2024-06-12 주식회사 비오엑스 테이프 없이 포장 가능한 포장상자
CN117447487A (zh) * 2022-07-19 2024-01-26 重庆圣华曦药业股份有限公司 一种利福昔明的纯化方法及其在利福昔明片剂中的应用
KR102756705B1 (ko) 2024-07-11 2025-01-21 주식회사 비오엑스 테이프 없이 포장가능한 보온, 보냉용 포장상자

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102015725A (zh) * 2008-02-25 2011-04-13 萨利克斯药品有限公司 利福昔明的多种形式及其用途

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE751182A (fr) 1969-05-30 1970-11-03 Takeda Chemical Industries Ltd Procede de fabrication d'antibiotiques
CH571064A5 (en) 1973-03-01 1975-12-31 Archifar Ind Chim Trentino Recovery of rieamycin from broths - by oxidn to an insol form
US4267274A (en) 1973-04-26 1981-05-12 Gruppo Lepetit S.P.A. Streptomyces mediterranei mutant capable of production of rifamycin B
GB1470426A (en) 1974-08-30 1977-04-14 Lepetit Spa Rifamycins
JPS6021570B2 (ja) * 1978-07-04 1985-05-28 三共株式会社 ド−パ類の高濃度製剤の製法
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
JPS57209211A (en) * 1981-06-18 1982-12-22 Shiseido Co Ltd Antimicrobial composition
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US4816568A (en) 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US5356625A (en) 1986-08-28 1994-10-18 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
GB8816620D0 (en) 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
CA2082809C (en) 1990-06-29 1995-10-17 Marino Nebuloni Pure crystalline form of rifapentine
US5284512A (en) 1991-03-06 1994-02-08 Donlar Corporation Polyaspartic acid and its salts for dispersing suspended solids
ATE227583T1 (de) 1991-12-20 2002-11-15 Novo Nordisk As Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
AU3582893A (en) 1992-01-13 1993-08-03 Pitman-Moore, Inc. Delayed release device for transition metal/protein complexes
WO1993019773A1 (en) 1992-04-07 1993-10-14 Pitman-Moore, Inc. Lyophilized somatotropin formulations
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
DE69739394D1 (de) 1996-10-16 2009-06-18 Napo Pharmaceuticals Inc Enteral-formulierungen von proanthocyanidzusammensetzungen gegen diarrhöe
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6042816A (en) 1998-08-19 2000-03-28 The Gillette Company Enhanced antiperspirant salts stabilized with calcium and concentrated aqueous solutions of such salts
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
CN100338028C (zh) 2000-10-31 2007-09-19 山道士有限公司 盐酸文拉法辛的晶形
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US6902723B2 (en) 2003-08-14 2005-06-07 The Gillette Company Enhanced efficacy antiperspirant compositions containing strontium
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US20050196418A1 (en) * 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
AU2007298733B2 (en) 2006-09-22 2012-11-08 Cipla Limited Rifaximin
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
US8974825B2 (en) 2007-07-06 2015-03-10 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
JP5755878B2 (ja) 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
PL2011486T5 (pl) 2007-07-06 2016-09-30 Lupin Ltd Farmaceutyczne kompozycje rifaksyminy
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
EP3628319B1 (en) * 2008-10-02 2024-02-14 Salix Pharmaceuticals, Ltd. Treatment of hepatic encephalopathy using rifaximin
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
WO2010044093A1 (en) 2008-10-16 2010-04-22 Strides Arcolab Limited Formulations containing rifaximin
KR101906177B1 (ko) 2008-12-10 2018-10-10 시플라 리미티드 리팍시민 복합체
IT1397617B1 (it) 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
ES2627655T3 (es) 2009-05-19 2017-07-31 Neuroderm Ltd Composiciones para la administración continua de inhibidores de DOPA descarboxilasa
PL2493471T3 (pl) 2009-10-26 2020-10-19 Borody Nowa skojarzona terapia jelitowa
MX346660B (es) 2009-10-27 2017-03-28 Lupin Ltd Dispersion solida de rifaximina.
WO2011061748A1 (en) 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
JP2013511569A (ja) 2009-11-23 2013-04-04 シプラ・リミテッド 局所用泡沫組成物
AU2010320656B2 (en) 2009-11-23 2015-07-30 Cipla Limited Topical foam composition
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
CN101773465B (zh) * 2010-01-19 2012-11-07 南京泛太化工医药研究所 以氨基酸为稳定剂的聚合物胶束载药系统
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CA2800235C (en) 2010-03-10 2018-10-16 Lupin Limited Rifaximin ready-to-use suspension
WO2011153444A1 (en) 2010-06-03 2011-12-08 Salix Pharmaceuticals, Ltd New forms of rifaximin and uses thereof
WO2011156897A2 (en) 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
SI2593463T1 (sl) 2010-07-12 2020-10-30 Salix Pharmaceuticals, Inc. Formulacije rifaksimina in njihove uporabe
CA2810598A1 (en) 2010-09-13 2012-03-22 Cipla Limited Pharmaceutical composition
WO2012035544A2 (en) 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
PT2672970T (pt) 2011-02-11 2018-10-11 Salix Pharmaceuticals Ltd Formas de rifaximina e suas utilizações
CA2834829A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110890A1 (it) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
EP2807148A4 (en) 2012-01-25 2015-04-08 Salix Pharmaceuticals Ltd RIFAXIMIN DERIVATIVE AND USES THEREOF
CA2876737A1 (en) 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
ITMI20131307A1 (it) 2013-08-02 2015-02-02 A M S A Anonima Materie Sint & Affini S P A Processo per la preparazione di refaximina k

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102015725A (zh) * 2008-02-25 2011-04-13 萨利克斯药品有限公司 利福昔明的多种形式及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Arginine-Assisted Solubilization System for Drug Substances: Solubility Experiment and Simulation;Atsushi Hirano等;《The Journal of Physcial Chemical B》;20101231;第114卷(第42期);13455–13462 *

Also Published As

Publication number Publication date
IL235992B (en) 2018-10-31
TN2014000530A1 (en) 2016-03-30
BR112015000088A8 (pt) 2017-12-26
EA201492126A1 (ru) 2015-06-30
WO2014006576A1 (en) 2014-01-09
CL2015000019A1 (es) 2015-06-26
DK2870163T3 (en) 2018-10-29
MX366193B (es) 2019-07-01
SG11201408277UA (en) 2015-02-27
EA028769B1 (ru) 2017-12-29
IN2014DN11207A (enExample) 2015-10-02
KR101880255B1 (ko) 2018-07-20
KR20150035998A (ko) 2015-04-07
CA2874815A1 (en) 2014-01-09
BR112015000088B1 (pt) 2020-04-28
PL2870163T3 (pl) 2019-03-29
IL235992A0 (en) 2015-02-01
US20140079783A1 (en) 2014-03-20
UA114512C2 (uk) 2017-06-26
AU2013285085B2 (en) 2017-06-08
JP2015522010A (ja) 2015-08-03
PT2870163T (pt) 2018-11-12
BR112015000088A2 (pt) 2017-06-27
ITBO20120368A1 (it) 2014-01-07
CN104395322A (zh) 2015-03-04
ZA201408990B (en) 2016-08-31
MX2014015799A (es) 2015-03-05
US9452157B2 (en) 2016-09-27
EP2870163B1 (en) 2018-09-19
NZ703120A (en) 2016-11-25
ES2691971T3 (es) 2018-11-29
JP6150888B2 (ja) 2017-06-21
CA2874815C (en) 2019-09-17
EP2870163A1 (en) 2015-05-13
AU2013285085A1 (en) 2015-01-15
EP3127909A1 (en) 2017-02-08
US20170189385A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
CN104395322B (zh) 含有利福昔明和氨基酸的药用组合物、其制备方法和用途
JP5932669B2 (ja) リファキシミン粉体、その調製方法、及び長期持続効果を得るために有用な前記リファキシミン含有徐放性組成物
AU2016364976B2 (en) Solid dispersions comprising a sGC stimulator
CN103826618A (zh) N-甲基-2-[3-((e)-2-吡啶-2-基-乙烯基)-1h-吲唑-6-基硫烷基]苯甲酰胺的药物组合物
EP2593463A1 (en) Formulations of rifaximin and uses thereof
JP2018531974A (ja) ブルトンチロシンキナーゼの阻害剤を含む剤形組成物
KR102362719B1 (ko) 리팍시민의 신규한 용매화 결정 형태, 생산물, 조성물 및 이의 용도
CN111825547B (zh) 一种芳基丙酸类化合物的盐及其制药用途
US10583087B2 (en) Pharmaceutical composition for oral administration
CA2588465C (en) Pharmaceutical composition containing an anti-nucleating agent
Singh et al. Characterization and relevance of physicochemical interactions among components of a novel multiparticulate formulation for colonic delivery
EP3389632A1 (en) Amorphous onapristone compositions and methods of making the same
HK1228392A1 (en) Crystalline forms of rifaximin and their preparation in the presence of amino acids
WO2017000270A1 (zh) 枸橼酸舍曲林的2种晶型及其制备方法
GR1010652B (el) Φαρμακευτικο σκευασμα που περιλαμβανει εναν αντιμικροβιακο παραγοντα και μεθοδος για την παρασκευη αυτου
CN110804057A (zh) 替比培南酯氢溴酸盐晶型及其制备方法、药物组合物和制药用途
CN111100122A (zh) 左旋四氢帕马丁新化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20171207

Address after: Milan Italy

Patentee after: Alpha Sigg Ma Co.

Address before: Italy Alan

Patentee before: ALFA WASSERMANN S.P.A.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20171220

Address after: Milan Italy

Patentee after: Alpha Sigg Ma Co.

Address before: Italy Alan

Patentee before: ALFA WASSERMANN S.P.A.

CP01 Change in the name or title of a patent holder

Address after: Milan Italy

Patentee after: Alpha sigma Co.,Ltd.

Address before: Milan Italy

Patentee before: Alpha Sigg Ma Co.

CP01 Change in the name or title of a patent holder
CP02 Change in the address of a patent holder

Address after: Bologna, Italy

Patentee after: Alpha sigma Co.,Ltd.

Address before: Milan Italy

Patentee before: Alpha sigma Co.,Ltd.

CP02 Change in the address of a patent holder
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170510

CF01 Termination of patent right due to non-payment of annual fee